← Back to Search

Monoclonal Antibodies

PF-07901800 (TTI-621) Escalation Phase - R/R Lymphoma for Blood Cancers

Phase 1

Waitlist Available

Research Sponsored by Trillium Therapeutics Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time from the date of first dose of study intervention until pd, or death due to any cause, whichever occurs first (assessed up to approximately 12 months)

Awards & highlights

Study Summary

This trial is testing a new drug, TTI-621, for people with cancer that has come back or doesn't respond to treatment.

Eligible Conditions

Blood Cancers
Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time from the date of first dose of study intervention until pd, or death due to any cause, whichever occurs first (assessed up to approximately 12 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time from the date of first dose of study intervention until pd, or death due to any cause, whichever occurs first (assessed up to approximately 12 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and time from the date of first dose of study intervention until pd, or death due to any cause, whichever occurs first (assessed up to approximately 12 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Phase 1a Dose Escalation (Part 1) - Dose Limiting Toxicity (DLT) (incidence and severity of AEs)

Phase 1b Dose Optimization (Part 4) - Dose Limiting Toxicity (DLT)

Phase 1b Expansion (Part 2 and 3) - incidence and severity of AEs

Secondary outcome measures

Phase 1a Escalation (Part 1) - Incidence of Anti-Drug Antibody (ADA) against PF-07901800

Phase 1a Escalation (Part 1) - Pharmacokinetics (PK): Area Under the Curve [AUC] from time 0 to 168 hours of PF-07901800

Phase 1a Escalation (Part 1) - Pharmacokinetics (PK): Maximum Serum Concentration [Cmax] of PF-07901800

+17 more

Trial Design

16Treatment groups

Experimental Treatment

Group I: T-Cell LymphomaExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group II: Small Cell Lung CancerExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group III: Rituximab CombinationExperimental Treatment1 Intervention

Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Rituximab for CD20 positive malignancies

Group IV: Peripheral T-Cell Lymphoma (PTCL)Experimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group V: Part 4: Cutaneous T-Cell Lymphoma (CTCL)Experimental Treatment1 Intervention

Monotherapy expansion Part 4 (Dose Optimization) cohort with PF-07901800 (TTI-621)

Group VI: PF-07901800 (TTI-621) Escalation Phase - R/R LymphomaExperimental Treatment1 Intervention

The Escalation Phase will include multiple doses of PF-07901800 (TTI-621)

Group VII: Nivolumab CombinationExperimental Treatment1 Intervention

Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Nivolumab for Hodgkin Lymphoma

Group VIII: Myeloproliferative NeoplasmsExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group IX: Myelodysplastic SyndromeExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group X: Multiple MyelomaExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group XI: Indolent B-Cell LymphomaExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group XII: Hodgkin LymphomaExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group XIII: Cutaneous T-Cell Lymphoma (CTCL)Experimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group XIV: Chronic Lymphocytic LeukemiaExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group XV: Aggressive B-Cell LymphomaExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Group XVI: Acute Myeloid LeukemiaExperimental Treatment1 Intervention

Monotherapy expansion cohort with PF-07901800 (TTI-621)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Trillium Therapeutics Inc.Lead Sponsor

6 Previous Clinical Trials

353 Total Patients Enrolled

PfizerLead Sponsor

4,570 Previous Clinical Trials

10,915,735 Total Patients Enrolled

Pfizer CT.gov Call CenterStudy DirectorPfizer

3,476 Previous Clinical Trials

8,091,931 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research project currently seeking participants?

"This research endeavor is no longer enrolling patients; it was initiated on January 31th 2016, and the most recent update took place in July 26th 2022. Fortunately, there are numerous alternative clinical trials for malignancies and TTI-621 that have open enrolment. Currently, 2725 studies pertain to hematologic diseases while 1112 investigations require participants of TTI-621."

Answered by AI

In what clinical contexts is TTI-621 typically employed?

"TTI-621 is a viable remedy for polyangium and can be prescribed to treat malignant neoplasms, unresectable melanoma, as well as squamous cell carcinoma."

Answered by AI

How many individuals are participating in this medical investigation?

"As of now, this particular trial is not actively recruiting. It was first introduced on January 31st 2016 and its most recent edit occurred on July 26th 2022. However, there are currently 2725 medical studies with malignancies as the primary research focus that are admitting patients; 1112 of them involve TTI-621 specifically."

Answered by AI

Are there any notable precedents for deploying TTI-621 in clinical trials?

"Initially tested in 1993, TTI-621 has been the subject of 1050 completed trials conducted at National Institutes of Health Clinical Center on Rockville Pike. Currently, 1112 active studies are taking place with many located in Austin and New jersey."

Answered by AI

Are there numerous locations in this city running the clinical trial?

"Currently, this clinical trial is recruiting from a grand total of 46 sites. These are located in Austin, Hackensack, Duarte and other cities across the United States. Patients should consider selecting their closest location to minimize any travel that may be required for participation."

Answered by AI